ABSTRACT
BACKGROUND: Deep venous thromboses (DVT) continue to cause significant morbidity in critically ill patients. Standard prophylaxis for high risk patients includes twice-daily dosing with 30 mg enoxaparin. Despite prophylaxis, DVT rates still exceed 10% to 15%. Anti-Xa levels are used to measure the activity of enoxaparin and 12-hour trough levels Subject(s)
Anticoagulants/administration & dosage
, Anticoagulants/pharmacokinetics
, Enoxaparin/administration & dosage
, Enoxaparin/pharmacokinetics
, Factor Xa/metabolism
, Venous Thrombosis/prevention & control
, Adult
, Female
, Humans
, Injury Severity Score
, Male
, Prospective Studies
, Risk Factors
, Ultrasonography, Doppler, Duplex
, Venous Thrombosis/diagnostic imaging
, Wounds and Injuries/blood
, Wounds and Injuries/complications
, Wounds and Injuries/surgery
